Strengths

Liquidity is solid with a 2.81 current ratio and 2.73 quick ratio, giving DRMA more near-term flexibility than weaker peers.

Net debt to EBITDA of 0.52 suggests modest leverage, which is structurally safer than highly levered peers and reduces refinancing pressure.

Cash conversion cycle at 0 indicates efficient working-capital management, supporting liquidity discipline relative to peers with longer cash cycles.

Weaknesses

ROIC of -2.47 shows capital is still destroying value, leaving DRMA structurally behind profitable peers on long-run returns.

The absence of positive margin disclosure alongside weak ROIC suggests limited operating leverage, which constrains peer-relative earnings power.

Low leverage does not offset weak profitability, because peers with stronger margins can compound value faster even with similar balance-sheet risk.

Opportunities

If management converts strong liquidity into higher-return deployment, DRMA can narrow the gap versus peers that already earn positive returns on capital.

A modest debt load gives DRMA more room than leveraged peers to fund working-capital or growth initiatives without immediate balance-sheet strain.

Improving operating efficiency would have outsized peer-relative impact because current returns are negative, so even small margin gains can materially change positioning.

Threats

Persistent negative ROIC threatens DRMA’s competitive standing, because peers with positive capital returns can reinvest faster and widen the gap.

If operating performance stays weak, liquidity strength may be consumed by ongoing losses, reducing the advantage versus better-performing peers.

Limited disclosed margin data increases uncertainty, and peers with clearer profitability trajectories may attract capital and customer confidence more easily.

Overall Score

DRMA’s balance sheet and liquidity are comparatively resilient, but persistent negative returns on capital leave its structural positioning weaker than most profitable peers.